Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 105

Similar articles for PubMed (Select 24993497)

1.

Vascular endothelial growth factor a inhibition in gastric cancer.

Park do J, Thomas NJ, Yoon C, Yoon SS.

Gastric Cancer. 2015 Jan;18(1):33-42. doi: 10.1007/s10120-014-0397-4. Epub 2014 Jul 4.

PMID:
24993497
2.

Targeting vascular endothelial growth factor (VEGF) pathway in gastric cancer: preclinical and clinical aspects.

Abdel-Rahman O.

Crit Rev Oncol Hematol. 2015 Jan;93(1):18-27. doi: 10.1016/j.critrevonc.2014.05.012. Epub 2014 Jun 10.

PMID:
24970311
3.

Ramucirumab for gastric cancer.

Shitara K, Ohtsu A.

Expert Rev Gastroenterol Hepatol. 2015 Feb;9(2):133-9. doi: 10.1586/17474124.2015.987754. Epub 2014 Nov 28.

PMID:
25431958
4.

Integration of novel agents in the treatment of colorectal cancer.

Iqbal S, Lenz HJ.

Cancer Chemother Pharmacol. 2004 Sep;54 Suppl 1:S32-9. Review.

PMID:
15309512
5.

Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.

Tol J, Punt CJ.

Clin Ther. 2010 Mar;32(3):437-53. doi: 10.1016/j.clinthera.2010.03.012. Review.

PMID:
20399983
6.

Ramucirumab and its use in gastric cancer treatment.

Bronte G, Galvano A, Cicero G, Passiglia F, Rolfo C, Bazan V, Russo A.

Drugs Today (Barc). 2014 Sep;50(9):613-21. doi: 10.1358/dot.2014.50.9.2207198.

PMID:
25313368
7.

Growing tumor vessels: more than one way to skin a cat - implications for angiogenesis targeted cancer therapies.

Leite de Oliveira R, Hamm A, Mazzone M.

Mol Aspects Med. 2011 Apr;32(2):71-87. doi: 10.1016/j.mam.2011.04.001. Epub 2011 Apr 22. Review.

PMID:
21540050
8.
9.

Targetting esophageal and gastric cancers with monoclonal antibodies.

Norguet E, Dahan L, Seitz JF.

Curr Top Med Chem. 2012;12(15):1678-82. Review.

PMID:
22978338
10.

Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer.

Wagner AD, Thomssen C, Haerting J, Unverzagt S.

Cochrane Database Syst Rev. 2012 Jul 11;7:CD008941. doi: 10.1002/14651858.CD008941.pub2. Review.

PMID:
22786517
11.
12.

Targeting angiogenesis in esophagogastric adenocarcinoma.

Okines AF, Reynolds AR, Cunningham D.

Oncologist. 2011;16(6):844-58. doi: 10.1634/theoncologist.2010-0387. Epub 2011 May 31. Review.

13.

Emerging mAbs for the treatment of esophagogastric cancer.

Ku GY, Ilson DH.

Expert Opin Emerg Drugs. 2015 Mar;20(1):63-74. doi: 10.1517/14728214.2015.983072. Epub 2014 Dec 6.

PMID:
25483267
14.

Molecular targeting to treat gastric cancer.

Aoyagi K, Kouhuji K, Kizaki J, Isobe T, Hashimoto K, Shirouzu K.

World J Gastroenterol. 2014 Oct 14;20(38):13741-55. doi: 10.3748/wjg.v20.i38.13741.

15.
16.

Clinical advances in the development of novel VEGFR2 inhibitors.

Fontanella C, Ongaro E, Bolzonello S, Guardascione M, Fasola G, Aprile G.

Ann Transl Med. 2014 Dec;2(12):123. doi: 10.3978/j.issn.2305-5839.2014.08.14. Review.

17.

Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors.

Cabebe E, Wakelee H.

Curr Treat Options Oncol. 2007 Feb;8(1):15-27. Review.

PMID:
17634832
18.

New drugs in cancer therapy, National Tumor Institute, Naples, 17-18 June 2004.

Caponigro F, Basile M, de Rosa V, Normanno N.

Anticancer Drugs. 2005 Feb;16(2):211-21.

PMID:
15655420
19.

Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic.

Ranieri G, Patruno R, Ruggieri E, Montemurro S, Valerio P, Ribatti D.

Curr Med Chem. 2006;13(16):1845-57. Review.

PMID:
16842197
20.

Incorporation of anti-angiogenesis therapy in the management of advanced ovarian carcinoma--mechanistics, review of phase III randomized clinical trials, and regulatory implications.

Eskander RN, Tewari KS.

Gynecol Oncol. 2014 Feb;132(2):496-505. doi: 10.1016/j.ygyno.2013.11.029. Epub 2013 Dec 3. Review.

PMID:
24316305
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk